State Street Holds 6.6% Of PTC Therapeutics In Passive Position

The holding covered 5,512,555 shares as of September 30, with State Street certifying it was not seeking to influence control.

Share
State Street Holds 6.6% Of PTC Therapeutics In Passive Position

State Street reported a 6.6% stake in PTC Therapeutics, which develops and sells medicines for rare disorders, in a passive ownership disclosure filed Tuesday. The holding comprised 5,512,555 common shares as of September 30, 2026, dating the position to that day rather than a purchase on the filing date.

Ownership Without A Control Campaign

State Street certified that the holding arose from its normal business activities and that it did not acquire or hold the shares to change or influence PTC's control.

State Street had shared voting authority over 5,230,730 shares and shared authority to dispose of 5,512,555 shares. It reported no sole voting or sole disposal authority.

PTC's Rare-Disorder Business

PTC's medicines primarily address neurological and metabolic disorders in children and adults. Its products include Sephience for phenylketonuria and Translarna and Emflaza for Duchenne muscular dystrophy.

PTC had a market value of $5.4 billion as of 9:08 a.m. ET Tuesday.

Sources

More on PTC Therapeutics

All PTC Therapeutics (PTCT) coverage →